Botulinum Toxin for Headache: a Comprehensive Review

被引:0
作者
Cheang, P. P. [1 ]
机构
[1] Maidstone & Tunbridge Wells NHS Trust, ENT Dept, Tunbridge Wells Hosp, Tonbridge Rd, Royal Tunbridge Wells TN2 4QJ, England
关键词
Headache; Migraine; Botulinum toxin; Botox; Review; PLACEBO-CONTROLLED PHASE; CHRONIC MIGRAINE; DOUBLE-BLIND; MYOFASCIAL PAIN; ONABOTULINUMTOXINA; INJECTION; PREDICTORS; EFFICACY; ADULTS; COST;
D O I
10.1007/s40136-020-00312-8
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Purpose of ReviewHeadache disorders are among the most prevalent disorders of mankind. They incur huge costs in terms of disability, days loss to work, and quality of life. In recent years, usage of botulinum toxin (BTX-A) has been extended to the management of various headaches. This review sets out to examine the evidence and role of BTX-A in the different headache disorders.Recent FindingsBTX-A is effective in reducing the frequency of chronic migraine days per month, with statistically significant improvement in quality of life. No difference was seen in patients with episodic migraine. The evidence of BTX-A on tension-type headache, cluster headache, and trigeminal neuralgia is emerging, but high quality large-scale studies are lacking at present. The mechanism of action of BTX-A on headaches is found to be independent of its effect on muscle contraction, where BTX-A is found to have direct anti-nociceptive effect on sensory nerves.SummaryBTX-A should be considered in the most refractory forms of chronic headaches. However, more RCTs are required in the future for higher-quality evidence and to guide injection sites and doses.
引用
收藏
页码:369 / 377
页数:9
相关论文
共 54 条
[41]   A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience [J].
Negro, Andrea ;
Curto, Martina ;
Lionetto, Luana ;
Martelletti, Paolo .
JOURNAL OF HEADACHE AND PAIN, 2016, 17 :1-9
[42]   Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition [J].
Olesen, Jes .
CEPHALALGIA, 2018, 38 (01) :1-211
[43]   Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology [J].
Pirazzini, Marco ;
Rossetto, Ornella ;
Eleopra, Roberto ;
Montecucco, Cesare .
PHARMACOLOGICAL REVIEWS, 2017, 69 (02) :200-235
[44]   Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia? [J].
Shehata, Hatem S. ;
El-Tamawy, Mohamed S. ;
Shalaby, Nevin M. ;
Ramzy, Gihan .
JOURNAL OF HEADACHE AND PAIN, 2013, 14 :92
[45]   Botulinum toxin type-A therapy in cluster headache: an open study [J].
Sostak, Petra ;
Krause, Phillip ;
Foerderreuther, Stefanie ;
Reinisch, Veronika ;
Straube, Andreas .
JOURNAL OF HEADACHE AND PAIN, 2007, 8 (04) :236-241
[46]  
Venancio RD, 2009, CRANIO, V27, P46
[47]   The diagnosis and treatment of chronic migraine [J].
Weatherall, Mark W. .
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2015, 6 (03) :115-123
[48]  
WHO, ATL HEAD DIS RES WOR
[49]   Evidence to Use Botulinum Toxin Injections in Tension-Type Headache Management: A Systematic Review [J].
Wieckiewicz, Mieszko ;
Grychowska, Natalia ;
Zietek, Marek ;
Wieckiewicz, Gniewko ;
Smardz, Joanna .
TOXINS, 2017, 9 (11)
[50]  
World Health Organization (WHO), 2016, Headache Disorders